The ClonoSEQ Receptor Detection Process
re-infused into the patient to restore the blood-producing cells. Prior detection of cancer cells in the autograft product has been shown to predict patient outcome, requiring the use of clonoSEQ to detect MRD.
ClonoSEQ is breaking further ground in the field of oncology, being more effective than most of the tests available nowadays. Beyond cancer, the technology could be useful in treating other diseases with a strong immune component, including autoimmune disorders such as rheumatoid arthritis, and infectious diseases, according to Adaptive Biotechnologies. Ultimately, ClonoSEQ is a positive step towards the once unfamiliar field of addressing relapse, and is a building block to fight MRDs.
" Detecting MRD Could Help Doctors Provide More Effective Care- Multiple Myeloma Research Foundation." Multiple Myeloma Research Foundation. MMRF, 14 Apr. 2015. Web. 18 Nov. 2016. < https:// www. themmrf. org / detecting-mrd-could-help-doctors-provide-moreeffective-care />.
" Adaptive Biotech Announces Expansion Of Clonoseq Minimal Residual Disease( MRD) Test." Adaptive Biotech Announces Expansion Of Clonoseq Minimal Residual Disease MRD Test. BioSpace, 4 Dec. 2015. Web. 18 Nov. 2016. < http:// www. biospace. com / News / adaptive-biotechannounces-expansion-of-clonoseq / 401939 >.
" Adaptive Biotechnologies’ ClonoSEQ ® MRD Test Can Be Used to Guide Post-Transplant Treatment Decisions in Multiple Myeloma Patients." Adaptive Biotechnologies’ ClonoSEQ ® MRD Test Can Be Used to Guide Post-Transplant Treatment. BusinessWire, 05 Dec. 2015. Web. 18 Nov. 2016. < http:// www. businesswire. com / news / home / 20151205005001 / en / Adaptive-Biotechnologies % E2 % 80 % 99-clonoSEQ % C2 % AE-MRD-Test- Guide-Post-Transplant >.
THE BELL NUCLEUS · Jan 2016 | 9